Targeting mitochondria in triple-negative breast cancer: Emerging therapeutic and drug development strategies
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-07 · 1881 (3) · 189591
DOI: 10.1016/j.bbcan.2026.189591 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-07. Verfasst von Ziyue Yuan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University,…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Mitochondria, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 377 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shenzhen Science and Technology Innovation Program, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Mitochondria are essential regulators of cell metabolism, apoptosis, and oxidative stress, rendering them critical targets for cancer therapy. This review systematically dissects the multifaceted roles of mitochondrial dysfunction in triple-negative breast cancer (TNBC), including its contributions to tumor initiation, progression, metabolic reprogramming, immune evasion, and programmed cell death, as well as its communication with other organelles. We summarize the current landscape of mitochondria-targeted therapeutic strategies for TNBC, encompassing direct targeting of mitochondrial proteins, indirect modulation of mitochondrial function via signaling pathways, mitochondria-targeted modification, and drug combination regimens. Additionally, we examine emerging approaches such as nanoparticle delivery systems and clinical compounds with mitochondrial regulatory effects. This review aims to provide a comprehensive framework for advancing the development of more precise and effective mitochondria-targeted therapies against TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.
- Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China; School of Pharmaceutical Sciences, Health Scie…
- School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen 518000, China. Electronic address: zhangjin1989@szu.edu.cn.
- Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China. Electronic address: zhanglanx_9@126.com.
Förderung
- National Natural Science Foundation of China
- Shenzhen Science and Technology Innovation Program
- Natural Science Foundation of Guangdong Province
- Southwest Jiaotong University
- Shenzhen University
Zitieren
APA
Yuan, Z., Mu, D., Chen, X., Yang, Q., Zhang, J., & Zhang, L. (2026). Targeting mitochondria in triple-negative breast cancer: Emerging therapeutic and drug development strategies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(3), 189591. https://doi.org/10.1016/j.bbcan.2026.189591
Vancouver
Yuan Z, Mu D, Chen X, Yang Q, Zhang J, Zhang L. Targeting mitochondria in triple-negative breast cancer: Emerging therapeutic and drug development strategies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(3):189591. doi:10.1016/j.bbcan.2026.189591
BibTeX
@article{Yuan2026,
author = {Yuan, Ziyue and Mu, Dan and Chen, Xiya and Yang, Qianqian and Zhang, Jin and Zhang, Lan},
title = {Targeting mitochondria in triple-negative breast cancer: Emerging therapeutic and drug development strategies},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {3},
pages = {189591},
doi = {10.1016/j.bbcan.2026.189591}
}
EUVIMED